Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer

Filippo De Marinis, V. Gebbia, L. De Petris

Research output: Contribution to journalArticlepeer-review


Neoadjuvant chemotherapy in potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) has become standard of treatment in the last years. Two randomised pioneer phase III trials conducted with second generation platinum combinations had demonstrated an advantage in survival of induction chemotherapy followed by surgery versus surgery alone. Subsequently, a wide number of phase II studies with third generation platinum-based doublets or triplets have increased the evidence of the activity as well as the good tolerability of this approach. Nowadays, the main topics of ongoing clinical research are to assess the role of induction chemotherapy in early stage disease, and the role of induction radiotherapy, as well as definite chemo-radiotherapy in stage IIIA NSCLC. This report review these issues and focuses on current treatment options for resectable stage IIIA-N2 NSCLC.

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 4
Publication statusPublished - May 2005


  • Early stage
  • Molecular markers analysis
  • Neoadjuvant chemotherapy
  • Neoadjuvant radiotherapy
  • Stage IIIA-N2

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this